Growing evidence suggests that targeting complementary metabolic pathways may provide greater protection for patients with type 2 diabetes. A systematic review and meta-analysis published in Diabetologia assessed the impact of combining sodium–glucose cotransporter 2 (SGLT2) inhibitors with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared with either drug alone.

Eighteen cohort studies including 1,164,774 individuals with type 2 diabetes were analyzed. The combination regimen was associated with a significantly lower risk of major adverse cardiovascular events (RR 0.56; 95% CI 0.43–0.71) and kidney composite outcomes (RR 0.48; 95% CI 0.32–0.73). Reductions were also observed in all-cause mortality (RR 0.50; 95% CI 0.40–0.63), cardiovascular mortality (RR 0.26; 95% CI 0.16–0.43), and hospitalization for heart failure (RR 0.67; 95% CI 0.64–0.71).

Safety profiles were similar between combination and monotherapy, with no increase in severe hypoglycemia, diabetic ketoacidosis, genitourinary infections, or gastrointestinal side effects. Although residual confounding remains a limitation, these findings indicate that dual SGLT2 inhibitor and GLP-1 RA therapy may enhance cardiorenal outcomes beyond either class alone.

Further randomized controlled trials are warranted to confirm efficacy, clarify safety, and guide integration of combination therapy into standard type 2 diabetes care.